Table 5.
Crude and overlap propensity score weighted odds ratios of H2 receptor antagonist (ref: nonuser) for mortality in esophageal cancer participants with subgroup analysis by the number of GERD episodes.
| Characteristics | Deceased Pts | Survived Pts | Odds Ratios for Mortality (95% Confidence Interval) | |||
|---|---|---|---|---|---|---|
| Exposure/Total (%) | Exposure/Total (%) | Crude | p | Overlap Weighted Model † | p | |
| Total participants (n = 811) | ||||||
| Exposure history | ||||||
| Current | 257/470 (54.7) | 130/341 (38.1) | 1.66 (1.17–2.34) | 0.004 * | 1.60 (1.12–2.28) | 0.010 * |
| Past | 102/470 (21.7) | 118/341 (34.6) | 0.72 (0.49–1.06) | 0.098 | 0.64 (0.43–0.96) | 0.030 * |
| Duration of H2RA use (days) | ||||||
| <30 | 191/470 (40.6) | 153/341 (44.9) | 1.05 (0.74–1.48) | 0.800 | 1.02 (0.71–1.45) | 0.924 |
| 30–90 | 94/470 (20.0) | 50/341 (14.7) | 1.58 (1.01–2.45) | 0.043 * | 1.49 (0.94–2.34) | 0.087 |
| ≥90 | 74/470 (15.7) | 45/341 (13.2) | 1.38 (0.87–2.19) | 0.174 | 1.37 (0.84–2.22) | 0.207 |
| GERD = 0 (n = 507) | ||||||
| Exposure history | ||||||
| Current | 164/315 (52.1) | 66/192 (34.4) | 1.84 (1.19–2.84) | 0.006 * | 1.66 (1.07–2.55) | 0.022 * |
| Past | 66/315 (21.0) | 63/192 (32.8) | 0.78 (0.48–1.25) | 0.296 | 0.60 (0.37–0.99) | 0.047 * |
| Duration of H2RA use (days) | ||||||
| <30 | 138/315 (43.8) | 85/192 (44.3) | 1.20 (0.79–1.84) | 0.392 | 1.16 (0.76–1.78) | 0.481 |
| 30–90 | 50/315 (15.9) | 22/192 (11.5) | 1.68 (0.93–3.06) | 0.088 | 1.29 (0.70–2.36) | 0.417 |
| ≥90 | 42/315 (13.3) | 22/192 (11.5) | 1.41 (0.77–2.60) | 0.265 | 0.96 (0.51–1.80) | 0.896 |
| GERD = 1 (n = 107) | ||||||
| Exposure history | ||||||
| Current | 30/50 (60.0) | 25/57 (43.9) | 2.40 (0.88–6.53) | 0.087 | 2.83 (0.69–11.50) | 0.147 |
| Past | 12/50 (24.0) | 16/57 (28.1) | 1.50 (0.48–4.65) | 0.483 | 1.47 (0.28–7.68) | 0.645 |
| Duration of H2RA use (days) | ||||||
| <30 | 24/50 (48.0) | 26/57 (45.6) | 1.85 (0.67–5.09) | 0.236 | 1.65 (0.40–6.79) | 0.490 |
| 30–90 | 12/50 (24.0) | 8/57 (14.0) | 3.0(0.87–10.29) | 0.081 | 4.78 (0.90–25.50) | 0.067 |
| ≥90 | 6/50 (12.0) | 7/57 (12.3) | 1.71 (0.43–6.83) | 0.445 | 3.84 (0.53–27.86) | 0.183 |
| GERD = 2 (n = 76) | ||||||
| Exposure history | ||||||
| Current | 27/42 (64.3) | 14/34 (41.2) | 1.07 (0.30–3.81) | 0.915 | 0.92 (0.16–5.33) | 0.924 |
| Past | 6/42 (14.3) | 15/34 (44.1) | 0.22 (0.05–0.94) | 0.042 * | 0.12 (0.01–0.95) | 0.044 * |
| Duration of H2RA use (days) | ||||||
| <30 | 14/42 (33.3) | 15/34 (44.1) | 0.52 (0.14–1.93) | 0.327 | 0.15 (0.02–1.26) | 0.081 |
| 30–90 | 12/42 (28.6) | 10/34 (29.4) | 0.67 (0.17–2.65) | 0.564 | 2.67 (0.25–28.71) | 0.419 |
| ≥90 | 7/42 (16.7) | 4/34 (11.8) | 0.97 (0.19–5.03) | 0.973 | 5.28 (0.32–88.20) | 0.247 |
| GERD ≥ 3 (n = 121) | ||||||
| Exposure history | ||||||
| Current | 36/63 (57.1) | 25/58 (43.1) | 1.44 (0.50–4.14) | 0.498 | 1.89 (0.53–6.78) | 0.327 |
| Past | 18/63 (28.6) | 24/58 (41.4) | 0.75 (0.25–2.27) | 0.611 | 0.72 (0.18–2.86) | 0.645 |
| Duration of H2RA use (days) | ||||||
| <30 | 15/63 (23.8) | 27/58 (46.6) | 0.56 (0.18–1.70) | 0.303 | 0.51 (0.12–2.10) | 0.349 |
| 30–90 | 20/63 (31.7) | 10/58 (17.2) | 2.00 (0.60–6.61) | 0.256 | 2.85 (0.59–13.78) | 0.193 |
| ≥90 | 19/63 (30.2) | 12/58 (20.7) | 1.58 (0.49–5.12) | 0.443 | 3.03 (0.68–13.43) | 0.145 |
Abbreviations: GERD, Gastroesophageal reflux disease; pts, Patients; H2RA, H2 receptor antagonist. * Significance at p < 0.05. † Adjusted for age, sex, income, region of residence, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, obesity, smoking, alcohol consumption, Charlson Comorbidity Index scores, GERD, and proton pump inhibitor.